论文部分内容阅读
为评价硫酸依替米星治疗细菌性下呼吸道感染的有效性和安全性 ,用硫酸依替米星治疗细菌性下呼吸道感染 30例。 30 0 mg,静脉滴注 ,每日 1次 ,平均疗程 7.5± 2 .3d。临床总有效率 83.3% ,细菌清除率82 .7% ,药敏试验显示分离病原菌对依替米星高度敏感率为 89.6 % ,高于庆大霉素 (P<0 .0 5 ) ,与奈替米星无显著差异 (P>0 .0 5 ) ,未见不良反应。结果表明依替米星治疗细菌性下呼吸道感染有效安全。
To evaluate the efficacy and safety of etimicin sulfate in the treatment of bacterial lower respiratory tract infections, 30 patients with bacterial lower respiratory tract infection were treated with etimicin sulfate. 30 0 mg, intravenous infusion, once daily, the average duration of 7.5 ± 2.3d. The total clinical effective rate was 83.3% and the bacterial clearance rate was 82.7%. The susceptibility test showed that the highly susceptible rate of etitidicum to isolated pathogens was 89.6%, higher than that of gentamicin (P <0.05) There was no significant difference between timolol (P> 0.05), no adverse reactions. The results show that etimicin is effective and safe in the treatment of bacterial lower respiratory tract infections.